Seattle Genetics

Seattle Genetics receives FDA Breakthrough Designation for ADCETRIS

Friday, November 11, 2016

Seattle Genetics, a global biotechnology company, has announced that the FDA granted Breakthrough Therapy designation to ADCETRIS (brentuximab vedotin) for the treatment of patients with CD30-expressing mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) who require systemic therapy and have received one prior systemic therapy. MF and pcALCL are the most common subtypes of cutaneous T-cell lymphoma (CTCL), accounting for more than 75% of the disease.

[Read More]

Seattle Genetics initiates phase I/II trial of Vadastuximab Talirine for MDS

Tuesday, February 23, 2016

Seattle Genetics has initiated a phase I/II clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) in patients with previously untreated myelodysplastic syndrome (MDS). 33A is an antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics’ newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. Azacitidine is a hypomethylating agent (HMA) commonly used in the treatment of MDS. MDS is known to be a precursor to acute myeloid leukemia (AML), and broadly expresses CD33.

[Read More]

Seattle Genetics, Bayer in ADC collaboration

Wednesday, June 26, 2013

Biotech Seattle Genetics has entered into an antibody-drug conjugate (ADC) collaboration with Bayer HealthCare. Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics also is eligible to receive up to $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products. 

[Read More]

Icon, DIA to deliver new educational product

Monday, February 11, 2013

Icon,a global provider of outsourced development, has formed a collaboration with DIA, a neutral, global, professional, member-driven association of nearly 18,000 pharmaceutical, biotechnology, and medical device professionals, to deliver the first solution-provider webinar, which offers free access to knowledge and innovative solutions to overcome some of the key challenges in medical product development.

[Read More]